M.D. Anderson Cancer Center: Mesothelioma, Malignant trials

The registry lists 10 Mesothelioma, Malignant studies with M.D. Anderson Cancer Center as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 5Phase 2 4Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant MesotheliomaCompletedNCT02959463Phase 1Results posted
• Phase II Trial of Alisertib (MLN8237) in Salvage Malignant MesotheliomaCompletedNCT02293005Phase 2Results posted
• A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare CancersSuspendedNCT05337735Phase 2
• Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid TumorsTerminatedNCT03420963Phase 1
• Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsActive, not recruitingNCT03074513Phase 2
• Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by SurgeryActive, not recruitingNCT03007030Phase 2
• Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing DecorticationWithdrawnNCT02511600Phase 3
• Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)CompletedNCT01134146Phase 1
• Dasatinib in Resectable Malignant Pleural MesotheliomaCompletedNCT00652574Phase 1
• Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant MesotheliomaCompletedNCT00402766Phase 1